Evidence map›Paper›PMID 41591256›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Universal Antibody-Engineered Lipid Nanoparticles Potentiate Chemo-Immunotherapy Against Triple-Negative Breast Cancer by Reprogramming Tumor Cell Metabolism.

Yeneng Dai, Jiaqi Wang, Yu Liu, Guanda Jiao, Yuheng Gu, Yang Liu, Shengyu Fu, Xing Fan, Jialin Li, Ziang Guo and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yeneng DaiCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Jiaqi WangCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Yu LiuCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Guanda JiaoCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Yuheng GuCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Yang LiuCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Shengyu FuCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Xing FanCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Jialin LiCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Ziang GuoCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
Kam Tong LeungDepartment of Paediatrics, the Chinese University of Hong Kong, Hong Kong, China.
Lipeng ZhuSchool of Life Sciences, Central South University, Changsha, China.
Qi ZhaoCancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.ORCID https://orcid.org/0000-0002-5969-6407

Funding

Natural Science Foundation of Guangdong Province 2023A1515010549Science and Technology Development Fund of Macau FDCT/0065/2025/ITP1Science and Technology Development Fund of Macau FDCT/0150/2025/AFJ FDCT/0009/2023/RIC
6 · The paper itself

Abstract

Despite the promise of combining chemotherapy and immunotherapy for triple-negative breast cancer (TNBC), challenges remain due to targeting deficiencies and accelerated T cell exhaustion within the immunosuppressive tumor microenvironment (TME). To address these limitations, we developed a drug-encapsulated lipid nanoparticle (LNP) system to reprogram tumor metabolism and reverse acquired immune tolerance. This LNP encapsulates the cytotoxic agent monomethyl auristatin E (MA) and the immunomodulator metformin (Met), followed by conjugated to a human receptor tyrosine kinase-like orphan receptor 1 antibody (ROR1 Ab) via an acid-labile linker. ROR1 Ab-mediated active targeting enables precise tumor localization through NIR-II fluorescence imaging, and enhances chemotherapeutic efficacy while minimizing off-target toxicity. Critically, metformin incorporated into the lipid formulation inhibits both membrane and cytoplasmic PD-L1 expression and reduces TGF-β1 levels by suppressing mitochondrial oxidative phosphorylation (OXPHOS), thereby restoring T lymphocyte activity and amplifying the immune response. This work demonstrates a novel approach to enhance TNBC treatment through targeted modulation of tumor metabolism and immune activation.

Indexed as

ImmunotherapyNanoparticlesOligopeptidesTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleHumansLiposomesMetabolic ReprogrammingMetforminMiceReceptor Tyrosine Kinase-like Orphan ReceptorsTumor MicroenvironmentLipid NanoparticlesLiposomesMetforminmonomethyl auristatin EOligopeptidesReceptor Tyrosine Kinase-like Orphan ReceptorsROR1 protein, humanchemo‐immunotherapylipid nanoparticlesmicroenvironment remodelingmitochondria metabolismROR1 antibody

Identifiers

PMID41591256
PMCPMC13045483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.